anti-botulinum toxin recombinant polyclonal hyperimmune

Anti-Botulinum Toxin Recombinant Polyclonal Hyperimmune is a laboratory-produced, high-potency recombinant polyclonal antibody drug designed to neutralize botulinum neurotoxins, particularly serotypes A and B. Unlike traditional plasma-derived or horse serum-based antitoxins, this therapy consists of a mixture of human or humanized monoclonal antibodies that bind to distinct epitopes on the botulinum neurotoxin molecule. The mechanism of action involves simultaneous binding by multiple antibodies to the toxin, which enhances neutralization potency and promotes rapid clearance from the body. This approach aims to overcome limitations in supply and safety associated with plasma-derived products and offers longer half-life compared to animal-derived antitoxins. The drug is being developed primarily for post-exposure treatment and potential prophylaxis against botulism, including use as a countermeasure for biothreat scenarios[1][3][5][8].

Other names

GIGA-2339GIGA2339GIGA 2339